Results 101 to 110 of about 15,493 (219)

Occult presentation of spinal epidural abscess

PM&R, EarlyView.
Rotem Hass, Vincenzo Pizzuti, Ashley Petrone, Brett Begley   +3 more
wiley   +1 more source

Ageing‐Associated Dysregulation of Myogenic Differentiation in Inclusion Body Myositis

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Skeletal muscle is a postmitotic tissue dependent on a complex and tightly regulated regeneration process involving numerous intracellular and extracellular factors, including myogenic regulatory factors (MRFs), cytokines and myokines. Quiescent satellite cells are activated by physiological stimuli, injury or other traumatic insults for the ...
Geert M. de Vries, Willem De Ridder, Jonathan Baets   +2 more
wiley   +1 more source

OUTPATIENT PHYSICAL THERAPY EVALUATION AND TREATMENT OF A PATIENT DIAGNOSED WITH SPORADIC INCLUSION BODY MYOSITIS: A CASE STUDY

International Journal of Physiotherapy, 2017
Background: Sporadic inclusion body myositis is an autoimmune and degenerative disorder of skeletal muscle that affects people at random. It most commonly begins as progressive weakness and atrophy of lower extremity musculature, beginning with the ...
Tyler Harrigfeld, Trent Jackman
doaj   +1 more source

[Polymyositis-dermatomyositis recognized during the follow-up of a patient with type 2 diabetes]. [PDF]

, 2012
Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature.
Csóka, Mária, Dankó, Katalin, Samer F,   +2 more
core   +2 more sources

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Polymorphic myopathological findings in a 77‐year‐old woman with oculo‐bulbo‐facial and distal weakness

Brain Pathology, EarlyView.
Michele Tosi, Angela Puma, Elena Faedo, Gianmarco Severa, Luisa Villa, Sabrina Sacconi, Edoardo Malfatti   +6 more
wiley   +1 more source

Tissue‐retained needles in people who inject drugs: A systematic review of case reports and series on clinical presentations, complications and management

Addiction, Volume 121, Issue 6, Page 1381-1397, June 2026.
Abstract Background and aims Tissue‐retained needles from intravenous drug use can cause rare but severe complications, ranging from local to systemic infections to needle embolization. Due to the limited evidence and the lack of epidemiological studies on the issue, we systematically reviewed the literature focusing on case reports and case series on ...
Heidi Laukkala, Anna Nevalainen, Irina Rinta‐Kiikka, Samuel Heikkilä, Sisu Kiuru, Markku Sumanen, Otso Arponen, Olli Nevalainen   +7 more
wiley   +1 more source

Myositis-specific and myositis-associated autoantibodies: their clinical characteristics and potential pathogenic roles

Immunological Medicine
In recent years, various myositis-specific and myositis-associated autoantibodies have been identified in idiopathic inflammatory myopathies, including dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and
Mariko Ogawa-Momohara, Yoshinao Muro
doaj   +1 more source

Újabb adatok a myositisspecifikus és -asszociált antitestekről juvenilis és felnőttkori myositisekben [PDF]

, 2016
Absztrakt Az idiopathiás inflammatorikus myopathiák ismeretlen etiológiájú heterogén betegségcsoportot képeznek. Az elmúlt évtizedekben a korai diagnózisnak és az azt követően elkezdett agresszív ...
Dankó, Katalin, Váncsa, Andrea
core   +1 more source

Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) such as semaglutide (SEM) and tirzepatide (TZP) were initially approved for type 2 diabetes management but are increasingly used for weight loss. Limited data exist on real‐world use among patients with rheumatic and musculoskeletal diseases (RMDs).
Nicholas P. McCormick, Cristiano S. Moura, Jingyi Zhang, Emily E. Holladay, Fenglong Xie, Tapan Mehta, Joshua F. Baker, Jeffrey R. Curtis   +7 more
wiley   +1 more source